CMS Proposes Repeal of Add-On Payment Path for Breakthrough Devices

Why It Matters

Removing the streamlined NTAP route may reduce financial incentives for breakthrough devices, slowing their market entry and affecting the U.S. med‑tech innovation ecosystem. The shift also signals tighter Medicare reimbursement standards that could reshape investment and development strategies.

Key Takeaways

• CMS aims to end NTAP alternative pathway FY2028
• All devices must now prove substantial clinical improvement
• Breakthrough‑device designations reached 164 in FY2025
• AdvaMed warns rollback may curb med‑tech innovation
• CMS seeks more evidence‑based Medicare payments

Pulse Analysis

The NTAP program was introduced to bridge the gap between rapid medical‑device innovation and Medicare’s traditional reimbursement timelines. By offering add‑on payments, CMS incentivized manufacturers to bring transformative technologies to patients faster, especially those granted breakthrough‑device status by the FDA. The 2020 alternative pathway removed the substantial‑clinical‑improvement hurdle, allowing select devices to qualify based on novelty and cost alone, a move praised for accelerating access to cutting‑edge therapies.

CMS’s proposed repeal re‑imposes the clinical‑improvement test for all NTAP applicants, arguing that a more rigorous evidentiary standard protects Medicare beneficiaries and ensures taxpayer dollars fund truly superior care. However, med‑tech companies—particularly small innovators—rely on the alternative pathway to offset development costs and achieve early market penetration. The loss of this financial cushion could delay product launches, increase pricing pressure, and shift R&D focus toward incremental upgrades rather than bold, high‑risk breakthroughs.

The broader policy shift reflects growing scrutiny of Medicare spending amid rising healthcare costs. Stakeholders are likely to lobby for a compromise that preserves some flexibility while addressing CMS’s concerns about limited evaluation processes. If the repeal proceeds, firms may seek alternative funding mechanisms, such as private payer contracts or venture capital, to sustain innovation pipelines. The outcome will shape the competitive landscape of U.S. medical technology and influence how quickly patients gain access to life‑saving devices.